Rubicon Research IPO

About Rubicon Research Company

Rubicon Research Limited, founded in 1999 and headquartered in Mumbai, India, is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of differentiated generic formulations and drug-device combination products for regulated markets. The company began as India’s first independent pharmaceutical product development firm and has grown significantly over two decades, expanding its expertise across multiple dosage forms including oral solids, liquids, ophthalmic, nasal, and injectable products, supported by a global footprint with facilities in India, Canada, and the US. It holds over 50 patents and has a diverse portfolio of approved and pipeline products, emphasizing innovation in drug delivery technologies, such as gastro-retentive excipients and fixed-dose combinations. Rubicon’s key strengths include robust R&D capabilities, global regulatory compliance, and specialized formulation skills, which enable it to partner with global pharmaceutical companies while also developing consumer healthcare and educational arms domestically. The company operates with a strong commitment to innovation, quality, and customer-centric solutions, engaging proactively with regulatory and market challenges to maintain leadership in the specialty pharmaceuticals sector.